Anticoagulation in extracorporeal circulation using recombinant hirudin: acase report

Citation
S. Beholz et al., Anticoagulation in extracorporeal circulation using recombinant hirudin: acase report, PERFUSION-U, 15(3), 2000, pp. 257-260
Citations number
22
Categorie Soggetti
Cardiovascular & Respiratory Systems
Journal title
PERFUSION-UK
ISSN journal
02676591 → ACNP
Volume
15
Issue
3
Year of publication
2000
Pages
257 - 260
Database
ISI
SICI code
0267-6591(200006)15:3<257:AIECUR>2.0.ZU;2-Y
Abstract
Heparin-induced thrombocytopenia (HIT) is a severe complication following t he application of heparin; antibodies against complexes of heparin and PDF4 initiate activation of platelets. This may lead to massive thrombembolism, which is associated with a slight and transient drop of platelets in HIT I or a drop below 50% after approximately 5 days in HIT II. Further administ ration of heparin has to be strictly avoided in these patients. Immunologic evidence for HIT can easily be obtained by the heparin-induced platelet ag gregation assay. If anticoagulation is necessary, different, alternative dr ugs are available. Recombinant hirudin (r-hirudin) is a well-established dr ug for safe anticoagulation. Monitoring is possible by estimating the plasm a level of r-hirudin from the ecarin-clotting time. We report a case of a p atient with prosthetic aortic valve endocarditis and HIT II who suffered fr om massive postoperative bleeding requiring massive substitution of blood c omponents and coagulants caused by free circulating r-hirudin due to the us e of a hemofilter.